As the "Mad Money" host always says, the game of Wall Street is about expectations. Take-Two Interactive Software reported earnings on Wednesday night, resulting in a skyrocket performance of over 10 percent on Thursday.  Cramer sat down with Take-Two CEO Strauss Zelnic, who he considers to be the most conservative CEO who will ever appear on "Mad Money" because of his reluctance to provide an evolved forecast for his company.  "Our story has been an organic growth story, we now have the capital to consider other strategic acquisitions that are creative and we are very focused. Last year we bought back $277 million in stock, so we have shown willingness towards returning capital to the shareholders as well," said Zelnic.  Read MoreCramer: Grand Theft Auto maker is no one-trick pony  On the flip side, Charles River Laboratories can't seem to catch a break. This company reported better than expected results, and the stock was still slammed because the company's competitor PAREXEL reported horrendous results, and took Charles River down with it.  Cramer spoke with Charles River CEO, James Foster to find out what he thinks could happen in the long-term.  This contract research organization not only provides research for well-known biotech companies, they are also testing Tekmira's Ebola drug in the battle to stop the epidemic.  "Drug companies are all about finding novel targets. If they can't find targets they can't develop drugs against them. That's what biotech companies are doing these days, and now with the companies that we are buying we will be able to discover the targets. Things like Ebola will be affected," said Foster.
Even after a big move from the Fed, "Mad Money" host Jim Cramer thinks there are some apologies owed to investors.